Fagron N.V. (ARSUF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Fagron N.V. (ARSUF) Healthcare & Pipeline Overview

Fagron N.V. is a specialized pharmaceutical compounding company, delivering personalized medicine solutions, raw materials, and educational support across a global footprint. With a focus on innovation in formulations and vehicles, it serves hospitals, pharmacies, clinics, and patients, addressing unique healthcare needs within the specialty and generic drug manufacturing sector.

What Is the Investment Thesis for ARSUF?

Fagron N.V. presents an investment profile centered on its specialized position within the growing personalized medicine market, supported by strong profitability metrics and a global operational footprint. The company's market capitalization stands at $2.02B, with a P/E ratio of 16.92, indicating investor confidence in its earnings potential relative to its industry. A robust gross margin of 51.5% and a profit margin of 9.6% highlight efficient operations and effective cost management, critical for sustained profitability in the healthcare sector. The low Beta of 0.31 suggests lower volatility compared to the broader market, potentially appealing to investors seeking stability. Growth catalysts include the increasing demand for tailored pharmaceutical solutions, expansion into new geographic markets, and continuous innovation in compounding formulations and delivery systems. The Fagron Academy also serves as a strategic asset, fostering professional development and strengthening relationships within the prescribing and dispensing communities. While trading on the OTC market introduces specific liquidity and disclosure considerations, Fagron's established global presence and consistent profitability metrics underpin its value proposition, driven by the fundamental need for personalized healthcare solutions.

Based on FMP financials and quantitative analysis

ARSUF Key Highlights

Market capitalization of $2.02B reflects the company's significant valuation within the specialty pharmaceutical sector.

• A P/E ratio of 16.92 indicates investor expectations for continued earnings growth relative to its current share price.
• Strong gross margin of 51.5% demonstrates efficient production and pricing power for its specialized compounding products and raw materials.
• Profit margin of 9.6% showcases the company's ability to convert revenue into net income, outperforming many standard pharmaceutical manufacturers.
• A low Beta of 0.31 suggests Fagron N.V.'s stock price exhibits less volatility compared to the overall market, offering relative stability.

Who Are ARSUF's Competitors?

ARSUF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ARSUF's Key Strengths?

Global presence across multiple continents provides diversified market access and revenue streams.

• Strong gross margin of 51.5% indicates efficient operations and pricing power for specialized products.
• Comprehensive offering includes raw materials, equipment, compounded medicines, and educational services.
• Established brand and innovation focus in personalized medicine and compounding since 1990.

What Are ARSUF's Weaknesses?

Reliance on the specialized and potentially smaller market of pharmaceutical compounding compared to mass-market drugs.

• Operations across diverse regions may introduce complexities in regulatory compliance and supply chain management.
• Trading on the OTC market may limit liquidity and investor visibility compared to major exchanges.
• Profit margin of 9.6% could be susceptible to fluctuations in raw material costs or increased R&D expenses.

What Could Drive ARSUF Stock Higher?

ARSUF catalyst: Expansion of Fagron Academy's educational programs into new regions, potentially increasing market influence and product adoption among healthcare professionals.

• Continuous innovation in pharmaceutical compounding formulations and vehicles, leading to new product launches and enhanced market offerings.
• Strategic partnerships or acquisitions in key geographic markets to expand distribution and market share for personalized medicine solutions.
• Regulatory approvals for new compounding raw materials or specialized formulations in specific jurisdictions, opening new revenue streams.

What Are the Key Risks for ARSUF?

Increased regulatory scrutiny or changes in pharmaceutical compounding regulations across its diverse operational regions could impact compliance costs and market access.

• Competition from other specialized compounding pharmacies or larger pharmaceutical companies entering the personalized medicine segment could erode market share.
• Fluctuations in the cost or availability of critical raw materials could compress profit margins, given the company's reliance on these inputs.
• The inherent risks associated with trading on the OTC market, including lower liquidity, wider bid-ask spreads, and limited public disclosure, may affect investor confidence and share price stability.
• Economic downturns in any of its key operational regions (Latin America, North America, Europe, Middle East, Africa) could reduce healthcare spending and demand for specialized compounded medicines.

What Are the Growth Opportunities for ARSUF?

• **Expansion in Personalized Medicine Market**: The global demand for personalized medicine is steadily increasing, driven by advancements in genomics, a better understanding of individual patient responses, and the need for tailored dosages or formulations. Fagron, as a dedicated pharmaceutical compounding company, is directly positioned to capitalize on this trend. By continuously innovating in concepts, vehicles, and formulations, the company can expand its offerings to address a wider range of patient needs, including those with allergies, specific delivery requirements, or rare diseases. This market is projected to grow significantly as healthcare systems increasingly adopt patient-centric approaches, offering Fagron a substantial runway for revenue growth through specialized product development and market penetration.
• **Geographic Market Penetration**: Fagron N.V. already operates across Latin America, North America, Europe, the Middle East, and Africa. There is significant opportunity to deepen its market penetration within these existing regions by expanding its distribution networks, forging new partnerships with hospitals and pharmacies, and increasing brand awareness. Furthermore, exploring new emerging markets with growing healthcare infrastructure and increasing demand for specialized medical solutions could unlock substantial growth. Each region presents unique regulatory environments and healthcare needs, allowing Fagron to tailor its product and service offerings for optimal local market relevance and capture, contributing to overall revenue diversification and resilience.
• **Innovation in Compounding Formulations and Vehicles**: Continuous research and development into novel compounding formulations and advanced drug delivery vehicles represent a core growth driver for Fagron. By introducing new, more effective, or patient-friendly options, the company can solidify its leadership in the personalized medicine space. This includes developing specialized bases for topical applications, unique oral dosage forms, or sterile preparations for specific clinical uses. Such innovations not only enhance patient outcomes but also provide Fagron with a competitive edge, allowing it to command premium pricing and attract a broader base of prescribers and pharmacists seeking cutting-edge solutions for their patients. The timeline for these innovations is ongoing, driven by continuous R&D investment.
• **Growth of Fagron Academy and Educational Services**: The Fagron Academy, which provides education and training to prescribers and pharmacists, is a strategic asset that can be further leveraged for growth. Expanding the reach and scope of these educational programs can not only generate direct revenue but also strengthen Fagron's relationships with healthcare professionals, positioning it as a thought leader and preferred partner in pharmaceutical compounding. Increased training can lead to greater adoption of Fagron's raw materials, vehicles, and compounded medicines. This also ensures a higher standard of practice in compounding, benefiting the entire industry. The market for professional medical education is robust, offering a stable, long-term growth opportunity.
• **Increased Demand for Raw Materials and Equipment**: As the global pharmaceutical compounding market expands, so too does the demand for high-quality raw materials, specialized utensils, and compounding equipment. Fagron's role as a supplier in this segment provides a foundational growth opportunity. By ensuring a reliable supply chain, maintaining stringent quality control, and expanding its catalog of essential compounding components, Fagron can capture a larger share of this ancillary market. This segment offers consistent revenue streams, as compounding pharmacies and hospitals require a steady supply of these inputs. The growth is directly tied to the overall expansion of personalized medicine and compounding practices worldwide, representing a stable and scalable business line for the company.

What Threats Does ARSUF Face?

• Stringent and evolving regulatory landscape for pharmaceutical compounding across different countries.
• Competition from other specialized compounding pharmacies or larger pharmaceutical companies entering the niche.
• Potential for supply chain disruptions affecting raw material availability or costs.
• Negative perceptions or increased scrutiny associated with OTC-traded securities.

What Are ARSUF's Competitive Advantages?

• Global operational footprint across multiple continents, providing diversified market access.
• Proprietary innovation in compounding concepts, vehicles, and formulations, offering unique solutions.
• Fagron Academy provides specialized education, fostering strong relationships with healthcare professionals and enhancing industry standards.
• Comprehensive product portfolio, from raw materials to finished compounded medicines, creates a one-stop-shop for compounding needs.
• Established reputation and expertise in a highly specialized and regulated segment of the pharmaceutical industry since 1990.

What Does ARSUF Do?

Fagron N.V., founded in Nazareth, Belgium in 1990, has evolved into a prominent global pharmaceutical compounding company dedicated to personalized medicine. Initially known as Arseus NV, the company rebranded to Fagron NV in January 2015, solidifying its focus on tailored healthcare solutions. Fagron's core business revolves around providing comprehensive personalized medicine care to a diverse client base, including hospitals, pharmacies, clinics, and individual patients. This involves a multi-faceted approach that extends beyond simple drug manufacturing. The company is a key innovator in the pharmaceutical compounding space, actively developing novel concepts, specialized vehicles, and advanced formulations designed to meet specific patient requirements that cannot be addressed by mass-produced medications. Fagron's product portfolio is extensive, encompassing the supply of high-quality raw materials essential for compounding, specialized utensils and equipment, semi-finished products, and a wide array of vehicles. Furthermore, it directly supplies both sterile and non-sterile compounded medicines, ensuring a broad spectrum of customized treatment options are available. To support the safe and effective practice of pharmaceutical compounding, Fagron operates the Fagron Academy, an educational and training program tailored for prescribers and pharmacists. This initiative underscores the company's commitment to advancing professional knowledge and best practices within the industry. With a significant operational presence spanning Latin America, North America, Europe, the Middle East, and Africa, Fagron N.V. maintains a robust international footprint, positioning itself as a crucial partner in the global personalized medicine landscape.

What Products and Services Does ARSUF Offer?

• Provides personalized medicine care through pharmaceutical compounding.
• Innovates concepts, vehicles, and formulations for pharmaceutical compounding.
• Supplies raw materials for compounding to pharmacies and hospitals.
• Offers utensils and equipment necessary for pharmaceutical compounding.
• Manufactures and supplies semi-finished products for compounding.
• Provides both sterile and non-sterile compounded medicines.
• Offers education and training programs through the Fagron Academy for prescribers and pharmacists.
• Operates globally across Latin America, North America, Europe, the Middle East, and Africa.

How Does ARSUF Make Money?

• Sells raw materials, utensils, and equipment for pharmaceutical compounding.
• Generates revenue from the sale of semi-finished products and specialized vehicles.
• Earns income from the direct supply of sterile and non-sterile compounded medicines.
• Provides educational and training services through the Fagron Academy to healthcare professionals.
• Innovates and licenses new compounding formulations and concepts.

What Industry Does ARSUF Operate In?

Fagron N.V. operates within the Drug Manufacturers - Specialty & Generic industry, a segment of the broader Healthcare sector characterized by diverse and evolving demands. The company's niche in pharmaceutical compounding positions it uniquely, addressing the growing global trend towards personalized medicine. This trend is driven by an increasing recognition that 'one-size-fits-all' medications are not always optimal, especially for patients with unique allergies, specific dosage requirements, or rare conditions. The market for compounded pharmaceuticals is expanding as healthcare providers seek customized solutions for patient care. Fagron competes by offering a comprehensive suite of services, from raw material supply and innovative formulations to educational programs, differentiating itself from large-scale generic manufacturers. Its global reach across multiple continents allows it to capitalize on varying regulatory landscapes and healthcare needs, establishing a strong presence in a specialized, yet critical, segment of the pharmaceutical market.

Who Are ARSUF's Key Customers?

• Hospitals requiring specialized compounded medications.
• Pharmacies seeking raw materials, equipment, and compounded solutions.
• Clinics needing tailored pharmaceutical preparations for patients.
• Individual patients benefiting from personalized medicine care.
• Prescribers and pharmacists participating in educational programs.

Fagron N.V. (ARSUF) Valuation Context

Valued at $2.02B, ARSUF is classified as a mid-cap stock. Relative to its peer group, ARSUF's quantitative score of 54/100 is roughly in line with the peer average of 60/100.

ARSUF Revenue & Earnings Trend

In Q2 FY2026, ARSUF generated $640.1M in top-line revenue, marking a sequential increase of 15.9%. The company recorded net income of $53.6M, with diluted EPS of $0.73. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, ARSUF averaged $0.70 in diluted EPS.

Company Profile

Fagron N.V. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Nazareth, BE. The company is led by CEO Rafael Padilla. ARSUF has traded publicly since 2017.

Return on equity for Fagron N.V. stands at 17.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.3%, showing how much profit it generates from its asset base. ARSUF trades at a trailing price-to-earnings ratio of 16.92, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 7.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.11 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.2%, the inverse of the P/E and a quick read on earnings relative to price.

Fagron N.V.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.50 places it in the safe zone, indicating low near-term bankruptcy risk.

ARSUF Financials

ARSUF Latest News

ARSUF Analyst Consensus

ARSUF MoonshotScore

Fagron N.V. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources